GB1121358A — Aerosol manufacture
Assigned to Bristol Myers Co · Expires 1968-07-24 · 58y expired
What this patent protects
A therapeutically effective amount of an anti-tussive agent is incorporated in an aqueous whipped-topping-type non-toxic aerosol foam composition in the form of an oil-in-water emulsion. The anti-tussive agent may be d-methorphan, d-methorphan hydrobromide or d-methorphan hydrob…
USPTO Abstract
A therapeutically effective amount of an anti-tussive agent is incorporated in an aqueous whipped-topping-type non-toxic aerosol foam composition in the form of an oil-in-water emulsion. The anti-tussive agent may be d-methorphan, d-methorphan hydrobromide or d-methorphan hydrobromide adsorbate. The composition may contain milk or cream or an emulsion of vegetable or mineral oil. The surfactant present may be a mono- or diglyceride, an acetylated mono- or di-glyceride, a lactated monoglyceride, a sorbitan ester or a polyoxethylene sorbitan ester. The propellant may be a "Freon" (Registered Trade Mark), nitrous oxide, carbon dioxide or nitrogen. Optional extras include methyl- or propyl-paraben, cetyldimethylbenzylammonium chloride, sorbic acid, benzoic acid, phenylephrine hydrochloride, sodium-CMC, sweeteners and flavours.ALSO:A therapeutically effective amount of an anti-tussive agent is incorporated in an aqueous whipped-topping-type non-toxic aerosol foam composition in the form of an oil-in-water emulsion. The anti-tussive agent may be d-methorphan, d-methorphan hydrobromide or d-methorphan hydrobromide adsorbate. The composition may contain milk or cream or an emulsion of vegetable or mineral oil. The surfactant present may be a mono- or di-glyceride, an acetylated mono- or di-glyceride, a lactated monoglyceride, a sorbitan ester or a polyoxethylene sorbitan ester. The propellant may be a "Freon" (Regd. T.M.), nitrous oxide, carbon dioxide or nitrogen. Optional extras include methyl-or propylparaben, cetyldimethylbenzylammonium chloride, sorbic acid, benzoic acid, phenylephrine hydrochloride, sodium-CMC, sweeteners and flavours.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.